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Isoflupredone acetate as ancillary 
therapy for bovine respiratory 
disease in high-risk stocker calves 
Claire Crews*, Jeremy Powell†, Elizabeth Kegley§, Jana Reynolds‡, 
and Pete Hornsby¶  
ABSTRACT
Bovine respiratory disease (BRD) is the most prevalent and devastating disease in U.S. feedlot 
cattle. This study evaluated the use of isoflupredone acetate in the treatment of BRD. Crossbred 
male beef calves (n = 192; body weight = 221 ± 3.9 kg) were acquired in two blocks from regional 
auction markets and transported to the University of Arkansas Stocker and Receiving Cattle Unit. 
Calves were observed daily for signs of respiratory illness. Antibiotic treatment was administered 
if calves displayed signs of respiratory illness and rectal temperature was ≥40 °C. Calves (n = 72) 
requiring antibiotic treatment were assigned randomly to either treatment 1 (florfenicol) or treat-
ment 2 (florfenicol plus isoflupredone acetate). Treatment efficacy was determined by rechecking 
the rectal temperature of treated cattle 48 hours post treatment. Blood was collected (at treatment 
and recheck) via jugular venipuncture to evaluate complete blood count. Weights were recorded 
on days 0, 14, 28, 45, and 46. No difference existed for medical cost (P = 0.54) or temperature at 
recheck (P = 0.43). Upon recheck, neutrophils were higher and lymphocytes were lower in calves 
that received isoflupredone acetate (P ≤ 0.04). No difference existed in overall white blood cell 
count at recheck (P = 0.67). Calves that received isoflupredone acetate tended to exhibit greater (P 
= 0.09) average daily gain (ADG) between days 14 and 28 of the study. Results indicate that using 
isoflupredone acetate as ancillary therapy in the treatment of BRD did not have a positive effect 
on overall ADG or medical costs.     
* Claire Crews is a 2014 Honors graduate with a major in Animal Science.
† Jeremy Powell, the faculty mentor, is a professor in the Department of Animal Science. 
§ Elizabeth Kegley is a professor in the Department of Animal Science.
‡ Jana Reynolds is a technical assistant in the Department of Animal Science.
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INTRODUCTION
Bovine respiratory disease (BRD) is the most preva-
lent and devastating disease in U.S. feedlot cattle. Every 
year, U.S. feedlot operations experience substantial eco-
nomic loss due to the pervasiveness of the disease. It is 
estimated that the U.S. cattle industry experiences an an-
nual economic loss of approximately $1 billion (Griffin, 
1997). Preventative and treatment costs are over $3 bil-
lion annually. 
There are many factors that contribute to the onset 
of bovine respiratory disease. The disease is often initi-
ated when an animal is exposed to one or multiple stress 
contributors, such as dust, transportation, overcrowding, 
commingling with infected animals, weaning, castration, 
or poor nutrition (Powell, 2010). These stressors cause 
the animal’s immune system to be suppressed, allowing 
viral and bacterial agents to enter and infect the body. 
The infection process usually begins with one or more 
viral agents, such as bovine viral diarrhea (BVD), infec-
tious bovine rhinotracheitis (IBR), parainfluenza type-3 
(PI3), or bovine respiratory syncytial virus (BRSV), en-
tering the host in response to a weakened immune sys-
tem due to various stressors. The viral infection hinders 
the immune system’s ability to fight off infectious bacte-
ria, such as Mannheimia haemolytica, Haemophilus som-
nus, or Pasteurella multiocida. Bacterial agents cause an 
even greater infection in the already-impaired respira-
tory tract, and the accumulation of these agents in the 
lungs can cause pneumonia (Faber et al., 1999). 
Bovine respiratory disease is characterized by depres-
sion, isolation from the herd, decreased appetite, in-
creased respiratory rate, fever, coughing, and nasal and/
or ocular discharge (Powell, 2010). A clinical illness score 
(Table 1) should be assigned to any animal identified as 
sick. A rectal temperature of ≥40 °C (normal temperature 
= 38.6 °C) is also commonly associated with the disease. 
Although antibiotics have been shown to be effective 
in treating BRD, many consumers are concerned that the 
excessive use of antibiotics may lead to the development 
of antibiotic-resistant bacteria in food animals (Hellwig 
et al., 2000). Non-steroidal anti-inflammatory drugs 
(NSAIDs) have proven to be beneficial in treating BRD 
when used in combination with antibiotics (Lockwood 
et al., 2003). These drugs do not impair the immune 
system and they help reduce pain and fever (Kaashoek 
et al., 1996; Lees, 2003). Steroidal anti-inflammatory 
drugs (SAIDs) have also been used as ancillary therapy, 
but studies have yielded conflicting results (Christie et 
al., 1977; Sustronck et al., 1997). These drugs have anti-
inflammatory properties, but they are also immunosup-
pressive (Smith, 1996). Isoflupredone acetate is a SAID 
that has recently shown favorable results when used as 
combination therapy. However, only one publication has 
scientifically evaluated the drug’s efficacy in the treatment 
of BRD. In that study, isoflupredone acetate prevented the 
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reduction in feed intake and average daily gain (ADG) in 
the first week after cattle were induced with the disease 
(Hewson et al., 2011). Faster clinical improvement was 
also seen in the cattle treated with isoflupredone acetate. 
Because this drug has not been extensively tested in cattle 
as ancillary therapy, there is a need for further data. This 
study was designed to provide supplementary data that 
can be used to evaluate the use of isoflupredone acetate 
in the treatment of BRD. 
The objectives of this study were to determine the ef-
ficacy of isoflupredone acetate as ancillary therapy for 
bovine respiratory disease and to determine the cost-
effectiveness of treatment using isoflupredone acetate as 
an adjunct to antibiotic treatment versus treatment using 
solely antibiotics.
MATERIALS AND METHODS
All methods used in this experiment followed the 
standard protocols that are used at the Stocker and Re-
ceiving Unit at the University of Arkansas System Divi-
sion of Agriculture Experiment Station in Savoy. Addi-
tionally, the methods used were reviewed and approved by 
the University of Arkansas Animal Care and Use Com-
mittee. 
The study utilized 192 commingled crossbred male 
beef calves (body weight = 221 ± 3.9 kg) acquired in two 
blocks (block 1 = 27 Sep 2012, block 2 = 11 Oct 2013). 
Calves were purchased from regional auction markets 
and transported to the University of Arkansas Stocker 
and Receiving Unit. Upon arrival (day -1), calves were 
individually weighed, identified with a uniquely num-
bered ear tag, and tested for a persistent infection of bo-
vine viral diarrhea virus (PI-BVDV) using the antigen 
capture ELISA ear notch test (CattleStats LLC, Oklahoma 
City, Okla.). Calves were kept commingled overnight and 
were given ad libitum access to bermudagrass hay and 
water. The following day (day 0), calves were reweighed, 
castrated by banding (if applicable), and inoculated with 
a 5-way modified-live virus vaccine (Pyramid 5, Boeh-
ringer Ingelheim Vetmedica, Inc., St. Joseph, Mo.) and 
an 8-way clostridial vaccine (Covexin 8®, Merck Animal 
Health, Summit, N.J.). Calves were also treated for inter-
nal parasites (Cydectin, Boehringer Ingelheim Vetmed-
ica, Inc.). They were then stratified by body weight and 
randomly assigned to 1 of 8 pens (0.42 ha) so that the 
average weights of the pens were similar. All calves were 
fed a grain supplement with a rate adjusted to a maxi-
mum of 1.9 kg per day per calf, which met or exceeded all 
nutrient requirements (NRC, 1996). The pre-determined 
quantity of feed was hand fed each morning (~8:30 a.m.). 
In addition, calves were given ad libitum access to ber-
mudagrass hay and water. 
Over the course of the 46-day study, all calves were 
observed daily (~8:00 a.m.) for signs of BRD. If 2 or more 
signs existed (i.e. depression, decreased appetite, cough-
ing, nasal or ocular discharge), calves were pulled from 
the group and rectal temperature was recorded via digi-
tal thermometer (GLA Agricultural Products, San Luis 
Obispo, Calif.). If rectal temperature was ≥40 °C, calves 
were treated with 1 of 2 treatment methods (based on a 
pre-assigned treatment randomization sheet). Calves as-
signed to treatment 1 (control) received an injection of 
florfenicol (6 mL/45.4 kg) (Nuflor, Intervet Schering-
Plough Animal Health, Summit, N.J.). Calves assigned 
to treatment 2 (ancillary therapy) received an injection 
of florfenicol (6 mL/45.4 kg) (Nuflor, Intervet Schering-
Plough Animal Health) plus an injection of isoflupredone 
acetate (5 mL/45.4 kg) (Predef 2X, Pfizer Animal Health, 
Kalamazoo, Mich.). All treated cattle were bled via jugu-
lar venipuncture (7 mL) into evacuated tubes (Vacutain-
er, BD Inc, Franklin Lakes, N.J.) upon initial treatment 
and 48 hours post-treatment to evaluate overall white 
blood cell (WBC) count. Calves were reevaluated 48 
hours post-treatment to determine if further antibiotic 
therapy was necessary. Usually cattle respond favorably 
1 
Table	  1.	  Clinical	  illness	  scores	  (CIS)	  for	  calves.	  
Score	   Description	   Appearance	  
1	   Slightly	  ill	   Mild	  depression,	  gaunt,	  +/-­‐	  ocular/nasal	  discharge	  
2	   Moderately	  ill	  
Ocular/nasal	  discharge,	  lags	  behind	  other	  animals	  in	  the	  
group,	  coughing,	  labored	  breathing,	  moderate	  depression,	  
+/-­‐	  rough	  hair	  coat,	  weight	  loss	  
3	   Severely	  ill	   Severe	  depression,	  labored	  breathing,	  purulent	  ocular/nasal	  discharge,	  not	  responsive	  to	  human	  approach	  
4	   Moribund	   Near	  death	  
Powell,	  2010.	  
 





Number, calves 38 34 -­‐-­‐
Time	  to	  second	  pull,	  days 9 13 0.37
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(80-85%) to the first line of treatment and no additional 
treatment is necessary (Edwards, 2010). Subsequent anti-
biotic therapy was administered if rectal temperature was 
still ≥40 °C or if the clinical illness score was greater than 
the initial score. Therapy 2, consisting of enrofloxacin 
(5.7 mL/45.4 kg) (Baytril, Bayer Animal Health, Shawnee 
Mission, Kan.), was given if calves failed to respond to 
the initial antibiotic therapy. Enrofloxacin was also ad-
ministered if calves responded to therapy 1 but relapsed 
less than 21 days after receiving therapy 1. Therapy 3, 
consisting of ceftiofur hydrochloride (2 mL/45.4 kg) (Ex-
cenel, Pfizer Animal Health), was administered if calves 
did not respond to therapy 2 after 48 hours. Calves that 
did not respond to therapy 3 were considered “chronic” 
and were given no further antibiotic treatment. Therapy 
3 was also used for calves that responded to therapy 2 but 
relapsed less than 21 days after receiving it.
Throughout the study, data were recorded for treat-
ment groups 1 and 2 on the basis of morbidity (fever re-
duction, repull rate, rate of clinical improvement, failed 
treatments, chronic illness), performance (ADG and to-
tal weight gained) and economics (cost of treatments). 
Blood samples were analyzed using a Cell-Dyn 1700 
Hematology Analyzer (Abbott Laboratory, Abbott Park, 
Ill.). Data were analyzed using the MIXED procedure of 
SAS (SAS Institute Inc, Cary, N.C.) to compare the effec-
tiveness of the two treatment methods. 
RESULTS AND DISCUSSION
Seventy-two out of 192 calves received treatment for 
respiratory illness. Thirty-eight calves received the con-
trol and 34 calves received the ancillary therapy (Table 2). 
Antibiotic treatments occurred between day 2 and day 
14 of the study. Body weights were recorded on day 0, 
14, 28, 45, and 46. Average daily gain over the entire 46-
day study was not different (P = 0.88) between treatment 
groups (Table 3). Calves that received isoflupredone ac-
etate tended to exhibit greater (P = 0.09) ADG between 
day 14 and day 28 of the study compared to calves that 
received only antibiotic therapy, 1.06 kg and 0.77 kg, 
respectively (Table 3). This result contrasts a study con-
ducted by Hewson et al. (2011), in which there were no 
differences in ADG throughout the study between calves 
that received isoflupredone acetate and calves that re-
ceived only antibiotic therapy. No difference was evident 
between treatment groups for medical cost (P = 0.54) or 
repull rate (P = 0.53) (Table 2). Body temperature at re-
check (P = 0.43) was also not different between treatment 
groups (Table 2). In Hewson’s study (2011), body temper-
ature was normalized sooner in the group that received 
isoflupredone acetate than in the group that received an-
tibiotic therapy alone. 
Upon recheck, neutrophils were higher and lympho-
cytes were lower in calves that received isoflupredone 
2 
Table	  2.	  Effects	  of	  isoflupredone	  acetate	  as	  ancillary	  therapy	  for	  bovine	  respiratory	  disease	  on	  morbidity.	  
Antibiotic	  
treatment	  
Antibiotic	  treatment	  with	  
isoflupredone	  acetate	   P-­‐value	  
Number	  of	  calves	   38	   34	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  -­‐-­‐	  
Time	  to	  second	  pull,	  days	   	  9	   13	   0.37	  
Calves	  treated	  two	  times	   	  9	   	  	  6	   0.53	  
Repull	  rate,	  %	   24	   18	   0.53	  
Calves	  treated	  three	  times	   	  4	   	  	  3	   0.81	  
Second	  relapse,	  %	   44	   50	   0.83	  
Medical	  cost,	  $	   	  	  	  	  	  	  21.73	   	  	  	  	  	  23.40	   0.54	  
Temperature	  at	  treatment,	  °C	   	  40.4	   	  	  	  40.6	   0.31	  
Temperature	  at	  recheck,	  °C	   	  39.5	   	  	  	  39.4	   0.43	  
3 
Table	  3.	  Effects	  of	  isoflupredone	  acetate	  as	  ancillary	  therapy	  for	  
bovine	  respiratory	  disease	  on	  growth	  performance.	  
Average	  daily	  gain	  (ADG)	  
period	   Antibiotic	  treatment	  
Antibiotic	  treatment	  with	  
isoflupredone	  acetate	   P-­‐value	  
Day	  0	  to	  day	  14,	  kg	   1.23	   1.03	   0.27	  
Day	  14	  to	  day	  28,	  kg	   0.77	   1.06	   0.09	  
Day	  28	  to	  day	  46,	  kg	   0.87	   0.76	   0.49	  
Total,	  kg	  	   0.95	   0.94	   0.88	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acetate (P ≤ 0.04) compared to calves that received only 
antibiotic therapy (Table 4). Consequently, the neutro-
phil to lymphocyte ratio was greater (P < 0.01) in calves 
that received isoflupredone acetate (Table 4). A higher 
neutrophil to lymphocyte ratio is an indication of stress 
which, in the case of this study, resulted from the admin-
istration of a drug that acts much like the natural stress 
hormone cortisol. It has been suggested that stress and 
viral infections may inhibit the recruitment of neutro-
phils to the lungs leaving a higher number in the pe-
ripheral blood (Caswell, 2014). No difference existed in 
overall WBC count at recheck (P = 0.67) (Table 4). This 
contrasts a study conducted by Sustronck et al. (1997) in 
which overall WBC count was significantly lower at re-
check in calves that received a SAID (flumethasone) in 
addition to antibiotic therapy in comparison to calves 
that received only antibiotic therapy.
Results indicate that treatment of bovine respiratory 
disease with isoflupredone acetate as ancillary therapy to 
an antibiotic regimen did not have a positive effect on 
overall ADG or medical costs. The reason that a SAID 
rather than a NSAID was chosen as ancillary therapy in 
this study, despite conflicting results, is because SAIDs 
block molecules higher in the inflammatory cascade 
(Tsurufuji et al., 1981). It was thought that cattle treated 
with a SAID in addition to antibiotics would recover 
faster from BRD because they would not experience the 
negative effects that occur as a result of the inflammatory 
response. Isoflupredone acetate, in particular, was cho-
sen in this study because it showed favorable results in 
the treatment of BRD during a study conducted by Hew-
son et al. (2011). The reason for the contrasting results 
between the current study and the study conducted by 
Hewson and colleagues is unknown. Perhaps replicating 
the current study using a larger sample group would yield 
results similar to those of Hewson and colleagues. Fur-
ther research of isoflupredone acetate is needed in order 
to better evaluate the drug’s effects on body weight gain 
performance and treatment expense. If this drug shows 
promising results in future studies, it could help prevent 
economic loss in the cattle industry due to poor perfor-
mance, reduced carcass value, or death.
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